ABT-100

farnesyltransferase inhibitor; structure in first source

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

1.	Neoplasms (Cancer) 11/01/2005 - "Here we report the preclinical anti-tumor activity of our most advanced FTase inhibitor (FTI), ABT-100, and a direct comparison with the current clinical candidates. " 04/15/2005 - "ABT-100 regressed EJ-1 tumors (2-12.5 mg/kg/d s.c., every day for 21 days) and showed significant efficacy in DLD-1, LX-1, MiaPaCa-2, or PC-3 tumor-bearing mice (6.25-50 mg/kg/d s.c. " 06/01/2005 - "Furthermore, ABT-100 inhibited Akt-dependent p27(Kip1) phosphorylation and this event was associated with increased levels of p27(Kip1) in the nucleus and reduced activity of the cyclin-dependent kinase 2. Moreover, ABT-100 treatment resulted in a significant reduction in tumor incidence and multiplicity. "
2.	Hepatocellular Carcinoma (Hepatoma) 06/01/2005 - "Taken together, these findings identify a mechanism of ABT-100 function and show the efficacy of ABT-100 as a chemopreventive agent of hepatocellular carcinoma."
3.	Liver Neoplasms (Liver Cancer) 06/01/2005 - "In the present study, we investigated the effects of a novel farnesyltransferase inhibitor, ABT-100, on human liver cancer cell lines, HepG2 and Huh7, and on an animal model of hepatocarcinogenesis. " 06/01/2005 - "Farnesyltransferase inhibitor, ABT-100, is a potent liver cancer chemopreventive agent."

1.	Cyclin-Dependent Kinase 2
2.	Farnesyltranstransferase (Farnesyltransferase)